Pierre Fabre Medicament

Quick facts

Marketed products

• DC071 · Other
• Placebo matching Tamsulosine Arrow LP · Urology
  This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin Arrow LP, a selective alpha-1A adrenergic receptor antagonist used in benign prostatic hyperplasia treatment.
• Placebo matching Tamsulosine LP · Urology
  This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin LP (long-acting tamsulosin) for use in clinical trials.
• Tamsulosine Arrow LP · Urology
  Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
• Tamsulosine LP

Phase 3 pipeline

• desonide 0.1% cream · Dermatology
  Desonide is a topical corticosteroid that reduces inflammation by inhibiting the production of pro-inflammatory mediators.
• Encorafenib and Binimetinib · Oncology
  Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells.
• F2695 · Oncology
  F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells.
• J022X ST · Oncology
  J022X ST is a tyrosine kinase inhibitor that targets specific molecular pathways involved in cancer cell proliferation and survival.
• Locapred@ · Dermatology
  Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions.
• Locatop@ · Dermatology
  Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors.
• V0034CR01B · Oncology
  This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
• vinflunine and best supportive care · Oncology
  Vinflunine is a chemotherapeutic agent that works by intercalating DNA and inhibiting the enzyme topoisomerase II, thereby inducing apoptosis in cancer cells.
• Vinflunine plus Capecitabine · Oncology
  Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.

Phase 2 pipeline

• Binimetinib Oral Tablet · Oncology
  MEK1/2 inhibitor
• F17464 · Diabetes
  F17464 is a small molecule that targets the SGLT2 receptor.
• MPFF
• Phytotherapy · Other
• Strefen · Other
• V0018
• V0116 transdermal patch
• V0162
• V0251
• Vinflunine, Carboplatin
• Vinorelbine cisplatin radiotherapy

Phase 1 pipeline

• Bronchodilatator · Respiratory
• KIN-2787
• KIN-2787 and binimetinib
• Reference treatment : Nicotine transdermal patch
• STX-241
• Test treatment : V0116 transdermal patch
• V0018 - B mg
• V0474 - A mg
• V0474 - B mg
• V0474 - C mg
• V0498 - A mg
• VERT-002

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pierre Fabre Medicament portfolio CI brief
• Pierre Fabre Medicament pipeline updates RSS